Although slower growth too so it is hard to compare. You probably can’t expect the same 9.x EV/EBITDA multiple that the 2016 offer was made on. This would mean an offer of $7+
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025